Annals of nuclear medicine · 2026
The anatomical distribution of metabolic tumor burden provides prognostic information beyond whole-body ¹⁸F-FDG PET/CT metrics in de novo metastatic HER2-positive breast cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Aksu Ayşegül, Ağartıoğlu Amine İrem, Güç Zeynep Gülsüm, Küçüker Kadir Alper, Özdal Ayşegül, Turgut Bülent
Аннотация
OBJECTIVE: Whole-body PET metrics quantify the magnitude of metastatic burden but ignore its anatomical distribution. Whether resolving metabolic burden according to anatomical compartment provides incremental prognostic information beyond conventional whole-body PET metrics remains unknown. We therefore tested whether the anatomical distribution of metabolic burden carries prognostic information beyond aggregate whole-body load in de novo metastatic HER2-positive breast cancer.
METHODS: Fifty-seven consecutive treatment-naive patients who underwent baseline ¹⁸F-FDG PET/CT before first-line anti-HER2 therapy were retrospectively analyzed. Compartment-specific metabolic parameters and clinical variables were evaluated using multivariable Cox regression. Model discrimination was internally validated over 1000 bootstrap resamples, and the incremental value of compartment-specific burden over whole-body metrics was evaluated with likelihood-ratio tests.
RESULTS: Twenty patients (35.1%) died during a median follow-up of 50.4 months. LN_MTV, Bone_TLG, and HR status independently predicted OS, yielding a model with a modest optimism-corrected C-index of 0.685 when the entire variable-selection sequence was repeated within each bootstrap resample. Adding compartment-specific metabolic burden improved models based on whole-body MTV or TLG (p = 0.003 and p = 0.001, respectively), whereas whole-body MTV provided no additional prognostic information once compartment-specific burden was considered (p = 0.90). Bone_TLG, but not binary bone involvement, independently predicted OS, and its prognostic contribution increased over time.
CONCLUSION: In this exploratory analysis, the anatomical distribution of metabolic tumor burden appeared to carry prognostic information beyond conventional whole-body PET metrics. These findings are hypothesis-generating, and prospective multicenter validation is warranted before compartment-specific metabolic phenotyping could inform clinical risk stratification in HER2-positive metastatic breast cancer.
METHODS: Fifty-seven consecutive treatment-naive patients who underwent baseline ¹⁸F-FDG PET/CT before first-line anti-HER2 therapy were retrospectively analyzed. Compartment-specific metabolic parameters and clinical variables were evaluated using multivariable Cox regression. Model discrimination was internally validated over 1000 bootstrap resamples, and the incremental value of compartment-specific burden over whole-body metrics was evaluated with likelihood-ratio tests.
RESULTS: Twenty patients (35.1%) died during a median follow-up of 50.4 months. LN_MTV, Bone_TLG, and HR status independently predicted OS, yielding a model with a modest optimism-corrected C-index of 0.685 when the entire variable-selection sequence was repeated within each bootstrap resample. Adding compartment-specific metabolic burden improved models based on whole-body MTV or TLG (p = 0.003 and p = 0.001, respectively), whereas whole-body MTV provided no additional prognostic information once compartment-specific burden was considered (p = 0.90). Bone_TLG, but not binary bone involvement, independently predicted OS, and its prognostic contribution increased over time.
CONCLUSION: In this exploratory analysis, the anatomical distribution of metabolic tumor burden appeared to carry prognostic information beyond conventional whole-body PET metrics. These findings are hypothesis-generating, and prospective multicenter validation is warranted before compartment-specific metabolic phenotyping could inform clinical risk stratification in HER2-positive metastatic breast cancer.